Pharmacokinetics of afatinib in subjects with mild or moderate hepatic impairment

被引：0
|
作者：
David Schnell
Susanne Buschke
Holger Fuchs
Dietmar Gansser
Rainer-Georg Goeldner
Martina Uttenreuther-Fischer
Peter Stopfer
Sven Wind
Marc Petersen-Sylla
Atef Halabi
Rüdiger Koenen
机构：
[1] Boehringer Ingelheim Pharma GmbH & Co KG,Translational Medicine and Clinical Pharmacology
[2] Boehringer Ingelheim Pharma GmbH & Co KG,Drug Metabolism and Pharmacokinetics
[3] Boehringer Ingelheim Pharma GmbH & Co KG,Global Biometrics and Clinical Applications
[4] Boehringer Ingelheim Pharma GmbH & Co KG,Clinical Development and Medical Affairs
[5] Kiel GmbH,Clinical Research Services (CRS)
来源：
Cancer Chemotherapy and Pharmacology | 2014年 / 74卷
关键词：
Afatinib; Hepatic impairment; Pharmacokinetics; Human; Epidermal growth factor receptor (EGFR); Tyrosine kinase inhibitor;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：267 / 275
页数：8
相关论文
共 50 条
  • [31] Lubeluzole pharmacokinetics in subjects with mild, moderate and severe renal impairment.
    Burstein, AH
    Lee, PID
    Gajjar, D
    Zhou, H
    Soo, Y
    Pesco-Koplowitz, L
    Hantson, L
    Woestenborghs, R
    Young, D
    [J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 1998, 63 (02) : 189 - 189
  • [32] FTY720 pharmacokinetics in mild to moderate hepatic impairment.
    Kovarik, JM
    Schmouder, RL
    Serra, D
    Wang, Y
    Lasseter, K
    [J]. AMERICAN JOURNAL OF TRANSPLANTATION, 2005, 5 : 473 - 473
  • [33] Effect of mild and moderate hepatic impairment on pharmacokinetics, pharmacodynamics, and safety of febuxostat
    Khosravan, R
    Grabowski, B
    Mayer, M
    Wu, JT
    Joseph-Ridge, N
    Vernillet, L
    [J]. JOURNAL OF CLINICAL PHARMACOLOGY, 2005, 45 (09): : 1083 - 1083
  • [34] Lack of effect of mild or moderate hepatic impairment on the pharmacokinetics of rimonabant.
    Grandison, Monica K.
    Kanamaluru, Vanaja
    Bishai, Raafat
    Lockwood, Graham
    Newton, John
    [J]. JOURNAL OF CLINICAL PHARMACOLOGY, 2007, 47 (09): : 1199 - 1199
  • [35] The Effects of Mild or Moderate Hepatic Impairment on the Pharmacokinetics, Safety, and Tolerability of Naloxegol
    Bui, Khanh
    She, Fahua
    Sostek, Mark
    [J]. JOURNAL OF CLINICAL PHARMACOLOGY, 2014, 54 (12): : 1368 - 1374
  • [36] The pharmacokinetics and safety of idelalisib in subjects with moderate or severe hepatic impairment.
    Jin, Feng
    Robeson, Michelle
    Zhou, Huafeng
    Hisoire, Grace
    Ramanathan, Srini
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [37] THE PHARMACOKINETICS AND SAFETY OF MOMELOTINIB IN SUBJECTS WITH MODERATE OR SEVERE HEPATIC IMPAIRMENT.
    Xin, Y.
    Collins, H.
    Cheng, F.
    Kwan, E.
    Ramanathan, S.
    Silverman, J. A.
    [J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 2016, 99 : S88 - S88
  • [38] Pharmacokinetics and pharmacodynamics of liposomal mifamurtide in adult volunteers with mild or moderate hepatic impairment
    Venkatakrishnan, Karthik
    Liu, Yi
    Noe, Dennis
    Mertz, Jaime
    Bargfrede, Michael
    Marbury, Thomas
    Farbakhsh, Kambiz
    Oliva, Cristina
    Milton, Ashley
    [J]. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2014, 77 (06) : 998 - 1010
  • [39] A Comparison Of Safety And Pharmacokinetics Of Esuberaprost (bps-314d-Mr) In Subjects With Normal, Mild And Moderate Hepatic Impairment
    Kessler, K. V.
    Marbury, T.
    Lasseter, K.
    Berg, J.
    Patel, G.
    Chen, X.
    Peychal, S.
    Shin, J.
    Sista, P.
    [J]. AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2016, 193
  • [40] Pharmacokinetics, safety and tolerability of a single oral dose of maraviroc in HIV-negative subjects with mild and moderate hepatic impairment
    Abel, Samantha
    Davis, John D.
    Ridgway, Caroline E.
    Hamlin, Julia C.
    Vourvahis, Manoli
    [J]. ANTIVIRAL THERAPY, 2009, 14 (06) : 831 - 837
12345